Top Pharmaceutical Companies in Los Angeles, CA (91)
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...
GoodRx's Top Stability & Growth Strengths
Product Line Growth: Feedback suggests newer offerings like Pharma Direct and subscriptions are expanding rapidly, indicating momentum beyond the legacy prescription-discount model.
Strategic Partnerships: Feedback suggests deepening relationships with pharmaceutical manufacturers are driving strong growth in Pharma Direct and expanding medication-access programs.
Healthy Cash Flow: Feedback suggests operating cash flow was strong in recent periods, even as total revenue was near flat and segment performance was mixed.
Clínica Monseñor Oscar A. Romero is a 501(c)(3) nonprofit Federally Qualified Health Center (FQHC) dedicated to providing quality, affordable, and culturally sensitive healthcare to underserved communities in greater Los Angeles. The clinic offers medical, dental, vision, pharmacy, and behavioral health services regardless of a patient's ability to pay, while honoring the legacy and teachings of Monseñor Oscar A. Romero.
PPD is now part of Thermo Fisher Scientific, the world leader in serving science. Together, Thermo Fisher and PPD are creating a unique opportunity to advance their shared pursuit to enable customers to make the world healthier by accelerating the development of new medicines. We now offer a comprehensive suite of world-class services across the clinical development spectrum – from...
.png)
Sleuth is a startup that delivers done-for-you competitive intelligence insights and reports to biopharma companies and investors. We use AI agents and a proprietary database of over 100M data points and documents to power bespoke analyses for executives and a range of business-focused teams across the industry. Among our current customers are some of the largest pharma companies in the...
RelaDyne, headquartered in Cincinnati, OH, combines many years of expertise with our valued associates to serve more than 10,000 clients in the automotive, commercial and industrial industries. We strive to deliver valuable, dependable service and effective solutions as a trusted partner to our customers. Our core business, focused on lubrication excellence, is accomplished through offering unmatched products and services in which...
RelaDyne LLC's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is widely cited as the nation’s largest lubricant distributor with leadership across lubricants, fuels/DEF, and industrial reliability services. Its standing in a fragmented market and industry recognition signal durable competitive advantages with large industrial and commercial clients.
Market Expansion: Feedback suggests sustained geographic growth to 190+ locations driven by an active acquisition program, including multiple deals in 2025–2026 that extend coverage across the West Coast, Midwest, and Northeast. The relocation of headquarters to Houston is framed as supporting additional scale, job growth, and proximity to key partners.
Investor Backing & Capital Strength: Private‑equity ownership and portfolio materials describing multibillion‑dollar scale indicate resources to continue organic expansion and M&A. This backing is repeatedly linked to momentum for further acquisitions and network densification.
At Solventum, we enable better, smarter, safer healthcare to improve lives. We never stop solving for you
Solventum's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is a leader or co‑leader in core niches such as negative‑pressure wound therapy and hospital coding/CDI software, with widely deployed platforms and recognized standings. Brand strength and installed bases across MedSurg, Dental, and HIS reinforce competitive positioning.
Resilient & Sustainable Growth: Recent quarters show positive organic sales growth, and guidance points to continued low‑single‑digit expansion. Feedback suggests momentum is supported across key segments, aligning with a steady, incremental trajectory.
Future-Ready Strategy: Management outlines a multi‑year plan centered on portfolio focus, R&D‑led innovation, and selective M&A to accelerate growth. Actions such as SKU rationalization, product launches, and targeted partnerships indicate preparation for longer‑term expansion.
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Market position is reinforced by being the largest pharmaceutical company in Asia, a consistent top‑15–20 global player by revenue, and operations across roughly 80 countries.
Innovation-Driven Growth: Innovation momentum is evident through a first‑in‑class FDA‑approved narcolepsy treatment and positive late‑stage results for oveporexton and zasocitinib. Multiple priority reviews and planned launches further support the pipeline.
Profitability: Profitability is strengthening with a sharp increase in net profit and a significant rise in operating profit, accompanied by an upgraded full‑year outlook. Cost discipline and transformation initiatives are also helping protect earnings while investment rises.
CG Oncology, Inc. (Nasdaq: CGON), is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life. Our lead candidate, cretostimogene grenadenorepvec, is an intravesically...
ALS Limited is a global leader in testing, inspection, certification, and verification services, providing comprehensive solutions across industries such as life sciences, minerals, industrial, and energy.
ALS Limited's Top Stability & Growth Strengths
Strong Revenue Growth: Financial results highlight record revenue with double‑digit year‑on‑year increases, supported by organic expansion and acquisitions. Growth has been broad-based across the portfolio with standout momentum in the Commodities division.
Profitability: Earnings expanded faster than sales, with underlying profit and margins rising to new highs. Momentum includes strong EBIT growth and accelerating NPAT alongside ongoing business transformations.
Strong Market Position & Advantage: Positioning as a top‑tier global specialist—especially in minerals and environmental testing—supports commercial resilience. A large international laboratory network and recognized expertise (including PFAS capabilities) underpin competitive strength.
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as...
Daiichi Sankyo's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate sustained year-over-year revenue increases driven primarily by the oncology franchise, notably ENHERTU and DATROWAY. Management maintains forward revenue growth guidance while highlighting continued indication and geographic expansion for these assets.
Strategic Partnerships: Large, multi‑asset collaborations with AstraZeneca and Merck validate the DXd platform and provide capital, development support, and commercial reach. These alliances underpin scale‑up and reinforce the medium‑term growth outlook in oncology.
Strong Market Position & Advantage: The company is recognized as a leader in oncology antibody‑drug conjugates, with ENHERTU establishing leading shares in key indications and additional approvals broadening use. Category leadership is further supported by expanding first‑line and tumor‑agnostic indications.
Gemelli is a biotechnology company that specializes in the microbiome, and IBS diagnostics.
Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon’s flagship product, PROVENGE (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. More than 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with...
Sinclair is a global medical aesthetics company that specializes in manufacturing and commercializing a wide portfolio of injectable and EBD treatments to support a consumer's full aesthetic journey. As a wholly owned subsidiary of Huadong Medicine Company Limited, the company's products are available in more than 55 countries through a direct presence in key global markets and a network of...
Sinclair's Top Stability & Growth Strengths
Strong Market Position & Advantage: Sinclair is positioned as a top-tier U.S. broadcaster with one of the largest station portfolios and owned networks that extend national reach. It is widely characterized as a leading player in local TV and sports content, even as Nexstar holds the top spot.
Strong Revenue Growth: Recent 2026 quarters show year-over-year revenue gains and higher full-year guidance, supported by stronger political demand, improving local media trends, and stable distribution. Digital-led core advertising is noted as a contributor to the uptick.
Innovation-Driven Growth: The company plays a leading role in ATSC 3.0/NextGen TV through ONE Media and continues to build specialty assets such as Tennis Channel. These initiatives broaden technology and content platforms that can diversify growth beyond legacy broadcast.
We’re designing a better way to deliver and pay for health while engaging and guiding a community of members to live their best health. As a national, team-based medical group with a focus on wellbeing and prevention that extends beyond traditional sick care, we deliver Primary Health. An entirely new model of health, Primary Health is driven by an interdisciplinary...
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts,...
Alcon's Top Stability & Growth Strengths
Strong Market Position & Advantage: The business is positioned as a global leader in eye care with meaningful share in contact lenses and one of the largest installed bases in ophthalmic surgical equipment, supporting durable demand across geographies. Scale across Vision Care and Surgical also supports recurring revenue via consumables tied to the installed base.
Resilient & Sustainable Growth: Revenue is described as growing year over year with guidance calling for continued mid-single-digit constant-currency sales growth into 2026, supported by steady demand for essential procedures like cataract surgery. The company is also positioned to outpace broader eye-care market growth expectations per the provided outlook.
Healthy Cash Flow: Cash generation is described as strong, with operating cash flow and free cash flow at sizable levels that support ongoing investment and shareholder returns. This cash profile provides resilience against near-term cost headwinds and funding for launches and efficiency programs.
Booster Fuels, Inc. provides an app-based, on-demand mobile fuel delivery service, offering on-site gasoline, diesel, and renewable fuel options directly to corporate fleets and office parking lots. Using technology and 'Smart Tankers,' the company improves operational efficiency, supports the decarbonization of last-mile delivery, and eliminates the need for inefficient trips to gas stations for businesses and commuters.
PDC Pharmacy is a long-term care pharmacy that provides specialized pharmaceutical services for individuals with intellectual disabilities, autism, and behavioral health needs, exclusively serving provider agencies.
Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of cell and exosome-based therapeutics. Its lead product candidate, Deramiocel, is an allogeneic cell therapy currently in late-stage clinical development for the treatment of Duchenne muscular dystrophy (DMD). The company also leverages its proprietary StealthX™ exosome platform for the targeted delivery of therapeutic agents to treat...
reach52 is a Singapore-based healthtech social enterprise on a mission to redesign healthcare to reach the 52% of the world currently without access. They operate a fully integrated healthcare delivery model in emerging markets, leveraging community health educators and data-driven insights to provide affordable medicines, screening services, and health interventions through partnerships with governments, businesses, and social organizations.
